Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon gamma inhalation - RELIEF THERAPEUTICS Holding

Next Previous
Drug Profile

Interferon gamma inhalation - RELIEF THERAPEUTICS Holding

Latest Information Update: 13 Jul 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator mondoBIOTECH
  • Developer RELIEF THERAPEUTICS Holding
  • Class Antibacterials; Antineoplastics; Antivirals; Interferons; Lymphokines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity No
  • Available For Licensing Yes - Idiopathic pulmonary fibrosis

Highest Development Phases

  • Discontinued Idiopathic pulmonary fibrosis

Most Recent Events

  • 01 Jul 2022 Discontinued - Phase-II for Idiopathic pulmonary fibrosis, before July 2022 (Inhalation) (RELIEF THERAPEUTICS pipeline, July 2022)
  • 19 Sep 2016 Interferon gamma inhalation is available for licensing in USA, Europe as of 19 Sep 2016.
  • 19 Sep 2016 Phase-II clinical trials in Idiopathic pulmonary fibrosis (Inhalation)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top